GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Cyclically Adjusted PB Ratio

Diamyd Medical AB (OSTO:DMYD B) Cyclically Adjusted PB Ratio : 5.28 (As of Jun. 04, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Cyclically Adjusted PB Ratio?

As of today (2025-06-04), Diamyd Medical AB's current share price is kr9.88. Diamyd Medical AB's Cyclically Adjusted Book per Share for the quarter that ended in Feb. 2025 was kr1.87. Diamyd Medical AB's Cyclically Adjusted PB Ratio for today is 5.28.

The historical rank and industry rank for Diamyd Medical AB's Cyclically Adjusted PB Ratio or its related term are showing as below:

OSTO:DMYD B' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.63   Med: 6.86   Max: 16.65
Current: 4.71

During the past years, Diamyd Medical AB's highest Cyclically Adjusted PB Ratio was 16.65. The lowest was 1.63. And the median was 6.86.

OSTO:DMYD B's Cyclically Adjusted PB Ratio is ranked worse than
79.08% of 674 companies
in the Biotechnology industry
Industry Median: 1.475 vs OSTO:DMYD B: 4.71

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Diamyd Medical AB's adjusted book value per share data for the three months ended in Feb. 2025 was kr1.066. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr1.87 for the trailing ten years ended in Feb. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Diamyd Medical AB Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Diamyd Medical AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Cyclically Adjusted PB Ratio Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.66 11.23 7.19 4.89 8.59

Diamyd Medical AB Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.51 5.96 8.59 7.17 5.33

Competitive Comparison of Diamyd Medical AB's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Diamyd Medical AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Cyclically Adjusted PB Ratio falls into.


;
;

Diamyd Medical AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Diamyd Medical AB's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=9.88/1.87
=5.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamyd Medical AB's Cyclically Adjusted Book per Share for the quarter that ended in Feb. 2025 is calculated as:

For example, Diamyd Medical AB's adjusted Book Value per Share data for the three months ended in Feb. 2025 was:

Adj_Book=Book Value per Share/CPI of Feb. 2025 (Change)*Current CPI (Feb. 2025)
=1.066/133.7436*133.7436
=1.066

Current CPI (Feb. 2025) = 133.7436.

Diamyd Medical AB Quarterly Data

Book Value per Share CPI Adj_Book
201505 1.946 100.285 2.595
201508 1.371 99.829 1.837
201511 1.222 100.129 1.632
201602 1.031 100.253 1.375
201605 1.155 100.914 1.531
201608 0.849 100.968 1.125
201611 0.845 101.517 1.113
201702 0.628 102.037 0.823
201705 0.267 102.679 0.348
201708 1.495 103.138 1.939
201711 1.347 103.413 1.742
201802 1.151 103.678 1.485
201805 0.934 104.632 1.194
201808 0.742 105.197 0.943
201811 0.593 105.443 0.752
201902 1.130 105.641 1.431
201905 1.019 106.895 1.275
201908 0.882 106.716 1.105
201911 0.787 107.345 0.981
202002 1.308 106.742 1.639
202005 1.208 106.882 1.512
202008 1.018 107.571 1.266
202011 2.565 107.549 3.190
202102 2.783 108.190 3.440
202105 2.941 108.838 3.614
202108 2.570 109.780 3.131
202111 0.000 111.069 0.000
202202 3.600 112.834 4.267
202205 3.386 116.746 3.879
202208 2.708 120.573 3.004
202211 2.292 123.803 2.476
202302 1.976 126.321 2.092
202305 1.769 128.034 1.848
202308 1.966 129.560 2.029
202311 2.206 130.958 2.253
202402 1.900 132.046 1.924
202405 1.960 132.818 1.974
202408 1.456 132.052 1.475
202411 1.493 133.000 1.501
202502 1.066 133.744 1.066

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Diamyd Medical AB  (OSTO:DMYD B) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Diamyd Medical AB Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines